Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Efficacy of Albumin Paclitaxel Plus Carrelizumab Versus FLOT in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes--A Multi-center, Randomised, Open, Phase 3 Clinical Trial

NCT05610332 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT05610332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05610332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Efficacy of Albumin Paclitaxel Plus Carrelizumab Versus FLOT in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes--A Multi-center, Randomised, Open, Phase 3 Clinical Trial
Lead sponsor
Fujian Medical University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
November 1, 2022
Completion date
November 1, 2027
Enrollment
216 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric cancer